

Media Alert

IMCD completes the acquisition of Swiss based DCS Pharma AG

ROTTERDAM, The Netherlands (December 10, 2019) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and food ingredients, today announces that it successfully completed the acquisition of Swiss pharmaceutical distributor DCS Pharma AG.

With this acquisition IMCD acquired 90% of the shares in DCS Pharma AG. The remaining 10% will follow per 31 December 2021.

DCS Pharma AG headquartered in Basel, was founded in 2016 by the two Swiss pharmaceutical distributors Dolder AG and ChemSwiss AG and operates in eight markets such as Spain, Italy, Germany, Mexico, and China. In 2018, the company generated a revenue of CHF 68 million with 64 employees. DCS’ product portfolio covers a range of Active Pharmaceutical Ingredients for the pharmaceutical and nutraceutical industries.

About IMCD N.V.

IMCD is a market-leader in the sales, marketing and distribution of speciality chemicals and food ingredients. Its result-driven professionals provide market-focused solutions to suppliers and customers across EMEA, Asia-Pacific and Americas, offering a range of comprehensive product portfolios, including innovative formulations that embrace industry trends.

Listed at Euronext, Amsterdam (IMCD), IMCD realised revenues of € 2,379 million in 2018 with more than 2,800 employees in over 47 countries on 6 continents. IMCD's dedicated team of technical and commercial experts work in close partnership to tailor best in class solutions and provide value through expertise for around 43,000 customers and a diverse range of world class suppliers.

To find out more about IMCD, please visit www.imcdgroup.com or contact ir@imcdgroup.com

